2003
DOI: 10.1016/s0091-6749(03)01859-1
|View full text |Cite
|
Sign up to set email alerts
|

Inhaled Corticosteroids

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
19
0

Year Published

2004
2004
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 198 publications
(20 citation statements)
references
References 108 publications
0
19
0
Order By: Relevance
“…In regard to the high risk of adverse effects of glucocorticoids including diabetogenesis, osteoporosis, muscle wasting, skin thinning and weight gain [1, 30], and the above noted corticosteroid insensitivity, more effective anti-inflammatory therapeutic approaches are needed to explore. So, we used a mouse model of chronic exposure to ozone that leads to airway inflammation and lung destruction, to investigate whether IL-17mAb can overcome the glucocorticoids insensitivity.…”
Section: Introductionmentioning
confidence: 99%
“…In regard to the high risk of adverse effects of glucocorticoids including diabetogenesis, osteoporosis, muscle wasting, skin thinning and weight gain [1, 30], and the above noted corticosteroid insensitivity, more effective anti-inflammatory therapeutic approaches are needed to explore. So, we used a mouse model of chronic exposure to ozone that leads to airway inflammation and lung destruction, to investigate whether IL-17mAb can overcome the glucocorticoids insensitivity.…”
Section: Introductionmentioning
confidence: 99%
“…The number of studies concerning the effects of inhaled fluticasone propionate (FP) on the mineral status of bone is limited and results are conflicting [8,9]. Although large studies have reported no substantial risk of ICS on bone metabolism in children with asthma [10,11,12], there are no new data available as to long-term intermittent FP use and its effects on children’s bone metabolism and its associated biomarkers.…”
Section: Introductionmentioning
confidence: 99%
“…Only the unbound fraction of a drug in plasma is available for many pharmacokinetic and pharmacodynamic processes, such as membrane permeation and receptor binding [1][2][3]. In the case of inhaled corticosteroids, it is widely believed that high protein binding is desirable in order to minimise systemic side effects and hence maximise the therapeutic index [4][5][6]. For this reason it was necessary to have an appropriate screen for plasma protein binding in place during the lead optimisation stage of a glucocorticoid receptor agonist research programme.…”
Section: Introductionmentioning
confidence: 99%